Abstract
Triple-negative breast cancer (TNBC) cells tend to resist chemotherapy drugs, making it essential to find other therapiesto treat this aggressive cancer. The inhibition of BAG3 with YM-1 is an option because BAG3 is overexpressed in over50% of TNBC patients. BAG3 positively regulates the EGFR pathway and cell proliferation, which means inhibiting itcould reduce TNBC tumor size and lessen the recurrence of TNBC. This paper looks at xenografting BT-549 cell linesin mice and treating them with docetaxel, PBS, and YM-1 at various concentrations. Changes in the tumor are trackedusing the tumor volume and weight of the mice. The results of this work will provide a better understanding of howBAG3 inhibition impacts cell proliferation and whether it can be an indicator of TNBC recurrence. Studying YM-1gives patients more options and the chance to find the best treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
